Camp4 Therapeutics Corp
CAMP
Company Profile
Business description
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Contact
One Kendall Square
Building 1400 West, 3rd Floor
CambridgeMA02139
USAT: +1 617 651-8867
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
55
Stocks News & Analysis
stocks
Does SpaceX’s sky-high valuation make sense?
SpaceX’s $1.5 trillion valuation looks expensive and risky, but not irrational.
stocks
ASX healthcare leader sees further cuts to fair value
Fiercer competition expected to squeeze margins.
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,976.80 | 20.70 | 0.23% |
| CAC 40 | 8,041.81 | 15.55 | -0.19% |
| DAX 40 | 23,640.03 | 328.60 | -1.37% |
| Dow JONES (US) | 47,346.90 | 359.61 | -0.75% |
| FTSE 100 | 10,353.77 | 58.47 | -0.56% |
| HKSE | 25,898.76 | 61.14 | -0.24% |
| NASDAQ | 22,673.87 | 23.24 | -0.10% |
| Nikkei 225 | 55,025.37 | 776.98 | 1.43% |
| NZX 50 Index | 13,293.13 | 198.76 | 1.52% |
| S&P 500 | 6,763.74 | 17.74 | -0.26% |
| S&P/ASX 200 | 8,743.50 | 19.40 | 0.22% |
| SSE Composite Index | 4,133.43 | 10.29 | 0.25% |